* history of hypersensitivity to interferon or novaferon or any excipients of interferon or novaferon. * having received other antiviral treatments (favipiravir, remdesivir, interferon, etc.). * ctcae grade 3 or higher liver dysfunction (alt / ast\> 5uln) or renal dysfunction (egfr \<30 ml / min / 1.73 m2). * active infections or other medical conditions that contraindicate inhalation therapy. * inappropriate for inclusion in the clinical trial as determined by investigators.

* history of hypersensitivity to interferon or novaferon or any excipients of interferon or novaferon. * having received other antiviral treatments (favipiravir, remdesivir, interferon, etc.). * ctcae grade 3 or higher liver dysfunction (alt / ast\> 5uln) or renal dysfunction (egfr \<30 ml / min / 1.73 m2). * active infections or other medical conditions that contraindicate inhalation therapy. * inappropriate for inclusion in the clinical trial as determined by investigators.

- history of hypersensitivity to interferon or novaferon or any excipients of interferon or novaferon. - having received other antiviral treatments (favipiravir, remdesivir, interferon, etc.). - ctcae grade 3 or higher liver dysfunction (alt / ast> 5uln) or renal dysfunction (egfr <30 ml / min / 1.73 m2). - active infections or other medical conditions that contraindicate inhalation therapy. - inappropriate for inclusion in the clinical trial as determined by investigators.

- history of hypersensitivity to interferon or novaferon or any excipients of interferon or novaferon. - having received other antiviral treatments (favipiravir, remdesivir, interferon, etc.). - ctcae grade 3 or higher liver dysfunction (alt / ast> 5uln) or renal dysfunction (egfr <30 ml / min / 1.73 m2). - active infections or other medical conditions that contraindicate inhalation therapy. - inappropriate for inclusion in the clinical trial as determined by investigators.